Resection and Liver Transplantation for Hepatocellular Carcinoma

By Josep Llovet1 , 2, Myron Schwartz2, Vincenzo Mazzaferro3. Seminars in liver disease (Print), 2005

901 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Some centers have reported zero peri-operative mortality [176,183].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Some centers have reported zero peri-operative mortality [176,183].”
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (2008, neutral): “A 50 (61) 186 (83) 9 ) 16 (7) Child–Pugh class A — no. (%) 72 (88) 204 (97) 0.52”
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “Recurrence rate is higher in patients with overt HCC and unfortunately, despite some positive results in isolated randomised controlled trials (RCTs), no adjuvant therapies after complete resection/local ablation are currently accepted as standard of care in HCC [30].”
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, background): “Despite the lack of any trial showing the benefits of any adjuvant therapy, it is common practice to perform adjuvant therapy by ablation or chemoembolization, whereas chemotherapy has no efficacy.(63) These locoregional interventions may be effective at the individual level, but will not address th”